Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trial.
Mammen AL, Amato AA, Dimachkie MM, Chinoy H, Hussain Y, Lilleker JB, Pinal-Fernandez I, Allenbach Y, Boroojerdi B, Vanderkelen M, Delicha EM, Koendgen H, Farzaneh-Far R, Duda PW, Sayegh C, Benveniste O. Mammen AL, et al. Among authors: sayegh c. Lancet Rheumatol. 2023 Feb;5(2):e67-e76. doi: 10.1016/s2665-9913(23)00003-6. Epub 2023 Jan 24. Lancet Rheumatol. 2023. PMID: 36923454 Free PMC article.
Phase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria.
Kulasekararaj AG, Lehtinen AE, Forsyth C, Gandhi S, Griffin M, Körper S, Mikala G, Muus P, Overgaard U, Patriquin CJ, Pullon H, Shen YM, Spearing R, Szer J, De la Borderie G, Duda PW, Farzaneh-Far R, Ragunathan S, Sayegh CE, Vadysirisack DD, Schrezenmeier H. Kulasekararaj AG, et al. Among authors: sayegh ce. Haematologica. 2024 Mar 1;109(3):929-935. doi: 10.3324/haematol.2022.281780. Haematologica. 2024. PMID: 37534517 Free PMC article. Clinical Trial. No abstract available.
Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation.
Tang GQ, Tang Y, Dhamnaskar K, Hoarty MD, Vyasamneni R, Vadysirisack DD, Ma Z, Zhu N, Wang JG, Bu C, Cong B, Palmer E, Duda PW, Sayegh C, Ricardo A. Tang GQ, et al. Among authors: sayegh c. Front Immunol. 2023 Aug 9;14:1213920. doi: 10.3389/fimmu.2023.1213920. eCollection 2023. Front Immunol. 2023. PMID: 37622108 Free PMC article.
Corrigendum: Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation.
Tang GQ, Tang Y, Dhamnaskar K, Hoarty MD, Vyasamneni R, Vadysirisack DD, Ma Z, Zhu N, Wang JG, Bu C, Cong B, Palmer E, Duda PW, Sayegh C, Ricardo A. Tang GQ, et al. Among authors: sayegh c. Front Immunol. 2023 Sep 25;14:1282155. doi: 10.3389/fimmu.2023.1282155. eCollection 2023. Front Immunol. 2023. PMID: 37818356 Free PMC article.
Separating the Wheat from the Chaff among HLA-DQ Eplets.
Devriese M, Lemonnier FA, Lion J, Sayegh C, Fleury E, Shofstall C, Giraldo L, Fiachetti Q, Usureau C, Miyadera H, Toutirais O, Mooney N, Lowe D, Taupin JL. Devriese M, et al. Among authors: sayegh c. J Immunol. 2024 Apr 22:ji2400030. doi: 10.4049/jimmunol.2400030. Online ahead of print. J Immunol. 2024. PMID: 38647382
53 results